Clinical Trial Update: Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 neoadjuvant study of axitinib plus avelumab for localized clear-cell renal cell carcinoma. The trial status is li…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• BAVENCIO (AVELUMAB)
• INLYTA (AXITINIB)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN